BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-130@pharmaconomics
DTSTAMP:20260707T003623Z
DTSTART;VALUE=DATE:20260731
DTEND;VALUE=DATE:20260801
SUMMARY:GSK Phase 2 — Flu mRNA (Formulation B1)
DESCRIPTION:Phase 2 trial results for Flu mRNA (Formulation B1) in Influenza\, Human are due Jul 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT07204964\n\nTrack it: https://pharmaconomics.com/e/130
URL:https://pharmaconomics.com/e/130
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GSK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR